Vor Biopharma posts narrower Q3 loss and advances clinical trial enrollment
Vor Biopharma reported a net loss of $86.7 million for the third quarter of 2026, a sharp improvement from the $812.7 million loss a year earlier, with no revenue in either period. The company finished enrolling patients in its UPSTREAM MG trial and expects the first read‑out of results in early 2027. It also announced that enrollment for a global Phase 3 ocular myasthenia gravis trial will begin in the first half of 2027 and that the Phase 3 Sjögren's disease trial dosed its first patient in March 2026. R&D spending rose for telitacicept programs while declining for legacy projects.
Why it matters
The reduced loss reflects a $757.6 million drop in warrant‑liability expense, extending the cash runway to early 2029 per the company’s statement. Progress on multiple Phase 3 trials could create future revenue streams if the programs succeed.
Key facts
- 1Net loss was $86.7 million in Q3 2026, compared with $812.7 million in Q3 2025. tradingview.com
- 2Diluted loss per share was $1.45, versus $121.63 a year earlier. tradingview.com
- 3Revenue was $0 in both Q3 2026 and Q3 2025. tradingview.com
- 4Enrollment in the UPSTREAM MG trial was finished in September 2026 and the company expects topline data in the first half of 2027. tradingview.com
- 5Cash and cash equivalents totaled $481.6 million as of September 30 2026, expected to fund operations into early 2029. seekingalpha.com
- 6The Phase 3 UPSTREAM ocular myasthenia gravis trial will start enrolling in the first half of 2027. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.